Aqua Regenerative Therapies’ proprietary nanogel competes on measured mechanism-level performance in biosensor enzyme stabilization and transdermal delivery. Its nanoScyl product is a glycosaminoglycan-based nanogel that stabilizes bioactive molecules and offers an animal-free alternative to the heparin nanoparticles developed at UCLA. The company is a biomaterials technology developer that also provides contract services to customers seeking expert technical advice, product prototyping, and process development, while its patented skin care technology is exclusive to the NeuLuna brand.
The BSA-glutaraldehyde approach is the enzyme-binding benchmark now used in the field. Against that benchmark, nanoScyl doubles initial activity, sustains signal for over 3 weeks, and improves the stability of implantable biosensor enzymes. Its transdermal delivery makes molecular diffusion through the stratum corneum depend on the internal phase nanogel diameter rather than the individual molecule’s molecular weight.
Quick Facts
When was Aqua Regenerative Therapies' last funding round?
Aqua Regenerative Therapies' most recent funding round was for $10k (USD) in June 2014.
How much disclosed funding has Aqua Regenerative Therapies raised?
As of Jun 7, 2014, Aqua Regenerative Therapies has disclosed funding of $10k (USD).
